ArticleNature cancer2022
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling.
Birgit Wilding et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
24 papers cite it
this papertrialcites it